Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rossana Dionisio
Observed name:
R. Dionisio
Institutions:
A. O. Ordine Mauriziano di Torino,
University of Turin
Observed institutions:
Peter MacCallum Cancer Centre,
John Radcliffe Hospital,
University of Oxford,
A. O. Ordine Mauriziano di Torino,
Ospedale San Luigi Gonzaga,
Istituti Ospitalieri di Cremona,
University of Turin
show all 7
ORCID:
0000-0003-4572-1277
Observed ORCID:
0000-0003-4572-1277
OpenAlex ID:
A5047304030
Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients
2006
·
Alberto Bottini
, Daniele Generali
, et al.
·
Journal of Clinical Oncology
·
200
PDF
Down-Regulation of Phosphatidylinositol 3′-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer
2008
·
Daniele Generali
, Stephen B. Fox
, et al.
·
Clinical Cancer Research
·
60
PDF
Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
2023
·
Anna Amela Valsecchi
, Rossana Dionisio
, et al.
·
Cancers
·
46
PDF
Management of cancer treatment–induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey
2024
·
Anna Amela Valsecchi
, Vittorio Fusco
, et al.
·
Tumori Journal
·
7
Adoption of electronic patient-reported outcomes in cancer clinical practice: the point of view of Italian patients
2024
·
A.A. Valsecchi
, V. Battista
, et al.
·
ESMO Real World Data and Digital Oncology
·
7
PDF
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis
2023
·
Chiara Pisano
, Fabio Turco
, et al.
·
Clinical Genitourinary Cancer
·
7
Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer
2023
·
Teresa Gamba
, Jessica Paparo
, et al.
·
Clinical Genitourinary Cancer
·
6
PDF
Gut and local microbiota in patients with cancer: increasing evidence and potential clinical applications
2024
·
Anna Amela Valsecchi
, Giorgia Ferrari
, et al.
·
Critical Reviews in Oncology/Hematology
·
4
PDF
Primary letrozole therapy versus the combination of letrozole plus oral cyclophosphamide in elderly breast cancer patients. A single Institution randomized phase II trial
2005
·
A. Bottini
, D. Generali
, et al.
·
Journal of Clinical Oncology
·
3
Clinical value of offering multiple chemotherapy lines to a luminal-like metastatic breast cancer: A case report with eribulin
2022
·
Anna Amela Valsecchi
, Jessica Paparo
, et al.
·
Tumori Journal
·
1
2088P Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
2023
·
A.A. Valsecchi
, V. Fusco
, et al.
·
Annals of Oncology
PDF
471P Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
2023
·
C. Paratore
, M. Audisio
, et al.
·
Annals of Oncology
PDF
Adoption of Patient-reported Outcomes in Clinical Practice for Older Patients Receiving Active Anti-cancer Treatment: Impact on Health-related Quality of Life
2021
·
C. Zichi
, F. De Vita
, et al.
·
Annals of Research in Oncology
Down-regulation of HIF-1α expression by letrozole in ER+ve breast cancer patients
2007
·
D. G. Generali
, A. Berruti
, et al.
·
Journal of Clinical Oncology
Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
2006
·
Stephen B. Fox
, Daniele Generali
, et al.
·
Breast Cancer Research and Treatment
Cytotoxic activity of three different schedules of epirubicin as primary chemotherapy in human breast cancer. A single-institution randomised phase II trial.
2006
·
Alberto Bottini
, Maria Pia Brizzi
, et al.
·
Breast Cancer Research and Treatment
Show more works
View as search
Works count:
16
Citation count:
341
H-index:
6
I10-index:
3
Year
Topic
Type